In order to test its Enterix Advanced technology in vivo, Mootral, a British biotech company, has completed the in vitro development and testing phase. Now, Mootral is launching a series of in vivo trials aimed at boosting the methane reduction effectiveness of the original EnterixTM product, while maintaining the productivity benefits needed for widespread farmer adoption of the product.
The Enterix Advanced patented technology harnesses the power of iodoform, a compound known for its methane-inhibiting properties, by combining it with specific active compounds from garlic which work synergistically to inhibit methane accumulation. Based on Mootral's original technology, which is already used on commercial farms in the UK, this approach builds on Mootral's original technology. In order to achieve significant emission reductions, there needs to be a strong synergy between these compounds that allows for significant reductions in emissions without detrimentally affecting dry matter intake and milk yield, which were potential issues previously associated with high doses of iodoform.
In order to achieve significant emission reductions, there needs to be a strong synergy between these compounds that allows for significant reductions in emissions without detrimentally affecting dry matter intake and milk yield, which were potential issues previously associated with high doses of iodoform.
With the help of Enterix Advanced, you can harness the power of the iodoform, which is known for its methane-inhibiting properties, by combining it with specific active compounds found in garlic of the highest quality.. It is based on the original technology developed by Mootral, which is already used by a number of commercial farms in the UK. It is this strong synergy between these compounds that enables significant emission reductions to be achieved without having a detrimental effect on dry matter intake and milk yield, a problem that was previously associated with high doses of iodoform in the feed.
It is this strong synergy between these compounds that enables significant emission reductions to be achieved without having a detrimental effect on dry matter intake and milk yield, a problem that was previously associated with high doses of iodoform in the feed.
By using Mootral's new technology, it is possible to produce a controlled release formulation for use in bolus administration to grazing cattle, thereby greatly increasing the potential for methane mitigation in animal agriculture globally. 
A known methane suppressant, iodoform has the same mode of action as bromoform, the active ingredient in some seaweed species proposed for methane reduction," said Thomas Hafner, Founder and CEO of Mootral. Firstly, it is a well-known compound that has already been approved for certain applications in human and animal health, is not carcinogenic and does not deplete the ozone, and is easily scaleable and affordable.
It is Mootral's philosophy of research and development to ensure efficacy, scalability, and farmer benefits are at the core of its R&D. As a result of Enterix Advanced's significant methane reduction, its applicability to both housed and grazing animals, and its productivity and animal health benefits, it is ideal for farmers to adopt. Additionally, there is no need for massive investments in order to scale this system up. 
In our view, the North Star is the desire to improve farmer economics and benefits so that animal agriculture can become a climate success. "We have found a solution that can be applied to any cow in any setting while making commercial sense for the farmer and being sustainable for the planet," Hafner added. 
The opportunity to reduce methane is both urgent - the gas traps 84 times more heat than carbon dioxide - and highly strategic - its reduction can have an immediate measurable impact on climate mitigation - and it can have an immediate and measurable impact on climate mitigation. As a matter of fact, nearly 30 percent of all methane emissions from human activity originate from enteric fermentation during cow digestion. 
There will be extensive in vivo trials taking place in 2024 with the aim to obtain regulatory approvals by the end of 2026. Mootral is speeding up the rollout of the technology with a plan to enroll as many as 300 million cows by the end of the decade.  
The photo can be found at https://mma.prnewswire.com/media/2290614/Mootral_Cows.jpg and the logo can be found at https://mma.prnewswire.com/media/2290615/Mootral_Logo.jpg
This week Mootral, a British company specializing in biotechnology, has announced that it has completed its development and test phases in vitro, and that it will begin its in vivo trials soon...
There has been an announcement from Mootral Limited, a British biotech company, that it has completed the in vitro development and testing phase and is now moving onto the in vivo testing phase...
Get PRN's top stories and curated news delivered to your inbox weekly when you sign up!

Source prnewswire